Aptose Biosciences Inc. (T:APS)

Business Focus: Biotechnology & Medical Research (NEC)

Get the company report for the most recent outlook updated daily

Mar 23, 2023 04:44 pm ET

Aptose Reports Results for the Fourth Quarter and Full Year 2022

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced financial results...

Mar 10, 2023 06:44 pm ET

Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank

Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, is aware of reports related to...

Mar 09, 2023 04:05 pm ET

Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the fourth quarter and full...

Mar 02, 2023 07:30 am ET

Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman,...

Jan 30, 2023 07:00 am ET

Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia

Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced the 120 mg monotherapy dosing of patients in the APTIVATE Phase 1/2 clinical trial of tuspetinib (formerly HM43239), an oral, mutation agnostic tyrosine kinase inhibitor...

Dec 28, 2022 07:30 am ET

Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman,...

Dec 12, 2022 06:15 am ET

Aptose Biosciences Establishes New At-The-Market Facility

Dec 11, 2022 09:00 am ET

Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations

Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today provided a clinical update of its lead oral myeloid kinome inhibitor, tuspetinib (formerly HM43239), as responses continue to emerge from a Phase 1/2 trial, and from its oral, dual...

Dec 07, 2022 04:05 pm ET

Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th

Nov 14, 2022 07:30 am ET

Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib

Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced dosing of the first patient to receive a continuous...

Nov 03, 2022 09:10 am ET

Aptose Clinical Data to be Presented at the 2022 ASH Annual Meeting

Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that clinical data for tuspetinib (formerly HM43239),...

Nov 01, 2022 04:01 pm ET

Aptose Reports Results for the Third Quarter 2022

Oct 18, 2022 04:01 pm ET

Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the quarter ended September...

Sep 14, 2022 07:30 am ET

Aptose to Participate in Cantor Oncology, Hematology & HemeOnc Conference

Sep 13, 2022 07:30 am ET

Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D.

Sep 12, 2022 07:30 am ET

Aptose’s New “G3” Formulation of Luxeptinib Boosts Bioavailability

Aug 30, 2022 07:30 am ET

Aptose to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 02, 2022 04:01 pm ET

Aptose Reports Results for the Second Quarter 2022

Jul 27, 2022 07:30 am ET

Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference

Jul 19, 2022 04:01 pm ET

Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022

Jun 27, 2022 07:30 am ET

Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer

Jun 02, 2022 08:10 pm ET

CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event

In a release issued under the same headline earlier today by Aptose Biosciences, Inc. (NASDAQ: APTO, TSX: APS), please note that in the section of updated clinical findings with HM43239, the fifth bullet point should read "Eight total responses,...

Jun 02, 2022 05:30 pm ET

Aptose Presents Highlights from Corporate Update and KOL Event

May 31, 2022 04:15 pm ET

Aptose Biosciences Announces Results of Annual Meeting of Shareholders

May 25, 2022 08:30 am ET

Aptose to Provide Program Updates at KOL Webinar on Thursday, June 2nd

Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that it will host a key opinion leader (KOL)...

May 12, 2022 10:00 am ET

Aptose to Hold KOL Event and Corporate Update Thursday, June 2nd

May 09, 2022 04:01 pm ET

Aptose Reports Results for the First Quarter 2022

May 04, 2022 07:30 am ET

Aptose Receives Fast Track Designation for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation

May 03, 2022 07:30 am ET

Aptose to Present at 2022 RBC Capital Markets Global Healthcare Conference

May 02, 2022 04:10 pm ET

Luxeptinib Preclinical Data Extend Potential Applications from Oncology to Inflammation

Apr 25, 2022 07:30 am ET

Aptose to Report First Quarter 2022 Financial Results and Hold Conference Call on Monday, May 9, 2022

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the quarter ended March 31,...

Apr 07, 2022 07:00 am ET

Aptose Announces Executive Management Changes

Mar 31, 2022 07:30 am ET

Aptose to Present at Canaccord Genuity’s 2022 Horizons in Oncology Virtual Conference

Mar 22, 2022 04:01 pm ET

Aptose Reports Results for the Fourth Quarter and Full Year 2021

Mar 08, 2022 07:30 am ET

Aptose to Report Fourth Quarter and Full Year 2021 Financial Results and Hold Conference Call on Tuesday, March 22, 2022

Mar 01, 2022 07:30 am ET

Aptose to Present at Oppenheimer’s 32nd Annual Healthcare Conference

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief...

Dec 29, 2021 07:30 am ET

Aptose to Participate in Two Biotech Events in January 2022

Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced that the company will participate in two separate biotech events in January 2022: the H.C. Wainwright BIOCONNECT Virtual Conference and the 11th Annual LifeSci Partners...

Dec 20, 2021 07:30 am ET

Aptose Provides Update on APTO-253 Program

Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced its decision to discontinue further clinical development of APTO-253. The decision follows prioritization of the company’s other more advanced pipeline candidates, as well...

Dec 13, 2021 04:30 pm ET

HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia

Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today reported that the oral myeloid kinome inhibitor HM43239 has demonstrated durable single agent activity in patients with relapsed or refractory acute myeloid leukemia (AML). Data were...

Nov 29, 2021 07:30 am ET

Aptose to Hold Corporate Update Monday, December 13th

Nov 22, 2021 04:02 pm ET

Aptose to Present at the Piper Sandler 33rd Annual Healthcare Conference

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will be participating in the...

Nov 11, 2021 04:01 pm ET

Aptose Reports Results for the Third Quarter 2021

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced financial results for the three months...

Nov 04, 2021 09:00 am ET

Aptose Clinical Data to be Presented at the 2021 ASH Annual Meeting

Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that clinical data for HM43239, a myeloid kinome...

Nov 04, 2021 06:00 am ET

Aptose Enters into Exclusive Worldwide License Agreement with Hanmi Pharmaceutical for Clinical-Stage Myeloid Kinome Inhibitor HM43239

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), announced today that it has entered into an exclusive license agreement with Hanmi Pharmaceutical, a South Korean pharmaceutical company, to develop and commercialize HM43239, an oral, highly...

Oct 26, 2021 07:30 am ET

Aptose to Report Third Quarter 2021 Financial Results and Hold Conference Call on Thursday, November 11, 2021

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will report financial results for the quarter ended September 30, 2021, and...

Oct 25, 2021 08:00 am ET

Aptose Expands Senior Leadership Team

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced the appointment of two key members to its management team to...

Aug 30, 2021 07:30 am ET

Aptose to Present at September Investor Conferences

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate at the...

Aug 03, 2021 04:01 pm ET

Aptose Reports Results for the Second Quarter 2021

Jul 20, 2021 04:01 pm ET

Aptose to Report Second Quarter 2021 Financial Results and Hold Conference Call on Tuesday, August 3, 2021

Jun 11, 2021 07:55 am ET

Aptose Presents Highlights from EHA During Corporate Update Event

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, is releasing highlights from a corporate update...

Jun 01, 2021 04:30 pm ET

Aptose Biosciences Announces Results of Annual Meeting of Shareholders

May 27, 2021 07:30 am ET

Aptose to Hold Corporate Update Friday, June 11th

May 12, 2021 07:30 am ET

Aptose to Present at Upcoming Investor Conferences

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate in upcoming...

May 04, 2021 04:01 pm ET

Aptose Reports Results for the First Quarter 2021

Apr 26, 2021 04:02 pm ET

Aptose to Report First Quarter 2021 Financial Results and Hold Conference Call on Tuesday, May 4, 2021

Apr 08, 2021 07:30 am ET

Aptose to Present at Canaccord Genuity 2021 Horizons in Oncology Virtual Conference

Mar 23, 2021 04:01 pm ET

Aptose Reports Results for the Fourth Quarter and Full Year 2020

Mar 16, 2021 07:30 am ET

Aptose Expands Senior Leadership Team

Mar 02, 2021 04:02 pm ET

Aptose to Release Fourth Quarter and Year End December 31, 2020 Financial Results and Hold Conference Call on March 23, 2021

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the year and quarter ended December 31,...

Dec 06, 2020 05:30 pm ET

Aptose Presents Highlights from ASH and Corporate Update Event

Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today released highlights from a corporate update event held on Sunday, December 6th, in conjunction with participation at the 2020 American Society of Hematology (ASH) Annual Meeting. The...

Dec 01, 2020 07:30 am ET

Aptose to Hold Corporate Update Sunday, December 6th

Nov 10, 2020 04:01 pm ET

Aptose Reports Results for the Third Quarter 2020

Nov 04, 2020 10:17 am ET

Aptose to Present CG-806 and APTO-253 Data at the 2020 ASH Annual Meeting

Oct 27, 2020 04:01 pm ET

Aptose to Release Third Quarter Ended September 30, 2020 Financial Results and Hold Conference Call on November 10, 2020

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended September 30, 2020 on...

Oct 19, 2020 07:00 am ET

Aptose Initiates Dosing of CG-806 in Patients with Acute Myeloid Leukemia

Sep 15, 2020 07:30 am ET

Aptose to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Sep 09, 2020 07:30 am ET

Aptose to Present at September Investor Conferences

Aug 06, 2020 07:30 am ET

Aptose Biosciences to Present at Canaccord Genuity 40th Annual Growth Conference

Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, Ph.D., President and Chief...

Aug 04, 2020 04:01 pm ET

Aptose Reports Results for the Second Quarter 2020

Jul 21, 2020 04:01 pm ET

Aptose to Release Second Quarter Ended June 30, 2020 Financial Results and Hold Conference Call on August 4, 2020

Jul 15, 2020 10:49 pm ET

Aptose Announces Pricing of Public Offering of Common Shares

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it priced its previously announced underwritten public offering of 10,500,000 common shares (the “Offering”) at a public offering price of US$5.25...

Jul 15, 2020 04:01 pm ET

Aptose Announces Proposed Public Offering of Common Shares

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS) today announced that it has commenced an underwritten public offering of its common shares (the “Offering”). In addition, Aptose intends to grant the underwriters a 30-day...

Jun 29, 2020 07:01 am ET

Aptose Announces FDA Allowance of IND for Phase 1a/b Study of CG-806 in Acute Myeloid Leukemia

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the U.S. Food and Drug Administration (FDA) completed its...

Jun 12, 2020 07:00 am ET

Aptose Presents Early Phase 1a/b CG-806 Clinical Findings at the 25th Congress of the European Hematology Association

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that new clinical data on CG-806,...

Jun 02, 2020 05:49 pm ET

Aptose Biosciences Announces Results of Annual Meeting of Shareholders

May 14, 2020 09:00 am ET

Aptose to Present Early CG-806 Clinical Findings at the 25th Congress of the European Hematology Association

May 07, 2020 07:30 am ET

Aptose to Present at 2020 RBC Capital Markets Global Healthcare Virtual Conference

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the company will participate in and hold investor...

May 05, 2020 04:17 pm ET

Aptose Biosciences Establishes New At-The-Market Facility

May 05, 2020 04:00 pm ET

Aptose Reports Results for the First Quarter 2020

Apr 27, 2020 10:59 am ET

IIROC Trade Resumption - APS

TORONTO, April 27, 2020 /CNW/ - Trading resumes in:

Apr 27, 2020 10:58 am ET

IIROC Trading Halt - APS

TORONTO, April 27, 2020 /CNW/ - The following issues have been halted by IIROC:

Apr 27, 2020 09:00 am ET

Aptose Presents Preliminary Clinical Data on CG-806 at AACR Virtual Annual Meeting 2020

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today presented the early clinical data on CG-806, the company’s oral,...

Apr 24, 2020 07:30 am ET

Aptose Biosciences Files Proxy Statement, Announces Online Only Annual General Meeting

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, announced today that it has filed its proxy statement...

Apr 21, 2020 07:30 am ET

Aptose to Release First Quarter Ended March 31, 2020 Financial Results and Hold Conference Call on May 5, 2020

Mar 10, 2020 04:02 pm ET

Aptose Reports Results for the Fourth Quarter and Full Year 2019

Feb 25, 2020 07:31 am ET

Aptose to Release Fourth Quarter and Year End December 31, 2019 Financial Results and Hold Conference Call on March 10, 2020

Jan 29, 2020 07:30 am ET

Aptose Biosciences to Host Key Opinion Leader Event Present at BIO CEO & Investor Conference

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the company will host a key opinion leader (KOL) event on...

Jan 07, 2020 07:30 am ET

Aptose Biosciences to Present at Biotech Showcase™ 2020 Conference

Dec 19, 2019 04:02 pm ET

Aptose Announces Closing of Public Offering of Common Shares

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced the closing of its previously announced underwritten public offering of 18,543,750 common shares (the “Offering”) at the public offering price of US$4.00...

Dec 17, 2019 08:00 am ET

Aptose Announces Pricing of Public Offering of Common Shares

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it priced its previously announced underwritten public offering of 16,125,000 common shares (the “Offering”) at a price of US$4.00 per share. Gross...

Dec 16, 2019 04:19 pm ET

Aptose Announces Proposed Public Offering of Common Shares

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it has commenced an underwritten public offering of its common shares (the “Offering”). In addition, Aptose intends to grant the Underwriters a...

Dec 09, 2019 11:00 am ET

Aptose Presents New Preclinical CG-806 Data at the 2019 ASH Annual Meeting

Dec 07, 2019 11:00 am ET

Aptose Presents Highlights From Corporate Event At ASH

Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) released highlights from a corporate event and clinical update today held at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, FL. The event was hosted by the...

Dec 04, 2019 07:30 am ET

Aptose Appoints Rafael Bejar, M.D., Ph.D., as Chief Medical Officer

Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the appointment of Rafael Bejar, M.D., Ph.D., to the position of...

Dec 02, 2019 07:30 am ET

Aptose to Present at 31st Annual Piper Jaffray Healthcare Conference

Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate in the 31st...

Nov 07, 2019 07:30 am ET

Aptose to Present at BIO-Europe Conference

Nov 06, 2019 09:54 am ET

Aptose to Present New CG-806 Data at the 2019 ASH Annual Meeting

Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company will be hosting an Event at the 61st...

Nov 05, 2019 04:02 pm ET

Aptose Reports Results for the Third Quarter Ended September 30, 2019

Oct 22, 2019 07:00 am ET

Aptose To Release Third Quarter Ended September 30, 2019 Financial Results and Hold Conference Call on November 5, 2019

Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of patients with...

Oct 10, 2019 07:30 am ET

Aptose to Participate at 5th International Conference on Acute Myeloid Leukemia of the European School of Haematology (ESH)

Sep 16, 2019 07:30 am ET

Aptose to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies

Aug 06, 2019 04:00 pm ET

Aptose Reports Results for the Second Quarter Ended June 30, 2019

Jul 30, 2019 07:30 am ET

Aptose Biosciences to Present at Canaccord Genuity 39th Annual Growth Conference

Jul 23, 2019 07:30 am ET

Aptose To Release Second Quarter Ended June 30, 2019 Financial Results and Hold Conference Call on August 6, 2019

Jul 16, 2019 07:05 am ET

Aptose Doses First CLL Patient in Phase 1 Study of CG-806 and Doses Third Cohort in Phase 1 Study of APTO-253

Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that dosing of CG-806, the company’s highly potent,...

Jun 14, 2019 07:00 am ET

Aptose Presents New Preclinical Data for CG-806 at the 24th Congress of the European Hematology Association

Jun 04, 2019 04:02 pm ET

Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders

Jun 03, 2019 09:00 am ET

Aptose Appoints Jotin Marango, M.D., Ph.D. as Chief Business Officer

Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the appointment of Jotin Marango, M.D., Ph.D., to the position...

Jun 03, 2019 08:38 am ET

Aptose Announces Closing of Public Offering of Common Shares

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced the closing of its previously announced underwritten public offering of 10,000,000 common shares at a price to the public of $1.85 per share, including...

May 31, 2019 08:00 am ET

Aptose to Present at the Jefferies 2019 Healthcare Conference

May 30, 2019 09:01 am ET

Aptose Announces Pricing of Public Offering of Common Shares

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it priced its previously announced underwritten public offering of 10,000,000 common shares at a price of $1.85 per share (the “Offering”) before...

May 29, 2019 04:22 pm ET

Aptose Announces Proposed Public Offering of Common Shares

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it has commenced an underwritten public offering of its Common Shares (the “Offering”). In addition, Aptose intends to grant the underwriters a...

May 24, 2019 05:43 pm ET

Aptose Biosciences Establishes New At-The-Market Facility

May 16, 2019 10:02 am ET

Aptose to Present New Preclinical Data for CG-806 at the 24th Congress of The European Hematology Association

May 13, 2019 08:15 am ET

Aptose to Present at May Investor Conferences

May 10, 2019 07:24 pm ET

Aptose Announces Commencement of Previously Announced $20.0 Million Common Share Purchase Agreement with Aspire Capital Fund, LLC

May 07, 2019 04:01 pm ET

Aptose Reports Results for the First Quarter Ended March 31, 2019

Apr 24, 2019 07:30 am ET

Aptose to Present at the Bloom Burton & Co. Healthcare Investor Conference 2019

Apr 23, 2019 07:30 am ET

Aptose To Release First Quarter Ended March 31, 2019 Financial Results and Hold Conference Call on May 7, 2019

Apr 02, 2019 07:00 am ET

Aptose to Present at the H.C. Wainwright Annual Global Life Sciences Conference

Apr 01, 2019 01:00 pm ET

Aptose Presents New Preclinical Data on CG-806 and APTO-253 at the 2019 AACR Annual Meeting

Mar 25, 2019 07:02 am ET

Aptose Announces FDA Allowance of Investigational New Drug Application for CG-806

Mar 12, 2019 04:02 pm ET

Aptose Reports Results for the Fourth Quarter and Year Ended December 31, 2018

Mar 07, 2019 07:00 am ET

Aptose to Participate in Upcoming Investor Conferences in March 2019

Mar 04, 2019 07:00 am ET

Aptose Biosciences and CrystalGenomics Announce Issuance of Australian Patent for CG-806

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that the Australian Patent Office (“APO”) has issued Australian Patent No. 2013371146 for CG-806, a first-in-class, highly potent oral small molecule...

Feb 28, 2019 07:00 am ET

Aptose to Present New CG-806 and APTO-253 Data at the 2019 AACR Annual Meeting

Feb 26, 2019 07:30 am ET

Aptose To Release Fourth Quarter and Year End December 31, 2018 Financial Results and Hold Conference Call on March 12, 2019

Feb 25, 2019 07:00 am ET

Aptose Biosciences Submits IND Application for CG-806

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it has submitted an Investigational New Drug (IND) application for CG-806 to the U.S. Food and Drug Administration (FDA) requesting approval to...

Feb 19, 2019 07:30 am ET

Aptose to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Jan 02, 2019 07:05 am ET

Aptose Biosciences to Present at Biotech Showcase™ 2019 Conference

Dec 12, 2018 10:00 am ET

Aptose Presents Highlights From CG-806 KOL Event

Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) released highlights from a Key Opinion Leader (KOL) breakfast featuring a presentation by Brian Druker, M.D., Professor of Medicine at the School of Medicine at Oregon Health & Science University...

Dec 03, 2018 07:10 am ET

OHSU and Aptose Present New CG-806 Preclinical Data at ASH 60th Annual Meeting

Oregon Health & Science University (OHSU) and Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) today announced the presentation of preclinical data demonstrating that CG-806, a first-in-class pan-FLT3/pan-BTK inhibitor, exhibits broad ex vivo...

Dec 03, 2018 07:05 am ET

Aptose Presents New Preclinical Data on CG-806 PAN-FLT3/PAN-BTK Inhibitor at ASH 60th Annual Meeting

Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) today announced the presentation of preclinical data from research led by The University of Texas MD Anderson Cancer Center exploring the mechanism by which CG-806, a highly potent pan-FLT3/pan-BTK...

Nov 26, 2018 07:05 am ET

Aptose Biosciences Doses First Patient in Re-Initiation of Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological Malignancies

Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that dosing has commenced in the first patient in its Phase 1b...

Nov 20, 2018 07:05 am ET

Aptose to Participate in Upcoming Investor Conferences, Host Key Opinion Leader Event, and Present Data at the Upcoming ASH Meeting

Nov 06, 2018 04:05 pm ET

Aptose Reports Results for the Third Quarter Ended September 30, 2018

Nov 01, 2018 09:26 am ET

Aptose to Present New CG-806 Data at the 2018 ASH Annual Meeting

Oct 23, 2018 07:05 am ET

Aptose to Release Third Quarter Ended September 30, 2018 Financial Results on November 6, 2018

Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, will release its financial results for the quarter ended September 30, 2018 on...

Sep 27, 2018 07:05 am ET

Aptose Biosciences and CrystalGenomics Announce Issuance of European Patent for CG-806

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that the European Patent Office (“EPO”) has issued European Patent No. EP2940014B1 for CG-806, a first-in-class, highly potent oral small molecule being...

Sep 25, 2018 07:05 am ET

Aptose to Present at Upcoming Investor Conferences in October 2018

Aug 29, 2018 07:05 am ET

Aptose to Present at Upcoming Investor Conferences in September 2018

Aug 15, 2018 07:05 am ET

Aptose Announces Appointment of Carol Ashe to Board of Directors

Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the appointment of Ms. Carol Ashe to the Board of Directors...

Aug 07, 2018 04:18 pm ET

Aptose Reports Results for the Second Quarter Ended June 30, 2018

Aug 02, 2018 07:05 am ET

Aptose Biosciences to Present at Canaccord Genuity 38th Annual Growth Conference

Jul 31, 2018 08:00 am ET

Aptose to Present at the 2018 Global Congress on Oncology and Cancer

Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, Ph.D., President and Chief...

Jul 24, 2018 07:05 am ET

Aptose To Release Second Quarter Ended June 30, 2018 Financial Results and Hold Conference Call on August 7, 2018

Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, will release its financial results for the quarter ended June 30, 2018 on...

Jul 10, 2018 07:00 am ET

Aptose Biosciences and CrystalGenomics Announce Issuance of Japanese Patent for CG-806

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), today announced that the Japan Patent Office has issued Japanese Patent No. 6325573 for CG-806. The granted patent claims various compounds, including the CG-806 compound,...

Jul 09, 2018 07:00 am ET

Aptose Biosciences to Participate at the Oppenheimer & Co. Inc. Boston Oncology Insight Summit and 1x1 Day

Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer and Gregory Chow, Senior Vice President and Chief Financial Officer, will participate at the upcoming...

Jun 29, 2018 07:00 am ET

FDA Lifts Clinical Hold so MYC Inhibitor APTO-253 Can Return to Phase 1b Trial In Patients With Hematologic Cancers

Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that it has lifted the clinical hold on APTO-253, Aptose’s investigational drug for hematologic cancers....

Jun 15, 2018 08:00 am ET

Aptose Presents New CG-806 Data at the 23rd Congress of the European Hematology Association

Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced the presentation of preclinical data demonstrating that CG-806, a highly potent pan-FLT3/pan-BTK inhibitor, exhibits a distinct mechanism of action and greater potency on...

Jun 14, 2018 07:05 am ET

Aptose Enters Into License Agreement With CrystalGenomics to Acquire CG-806 Rights in China

Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced that they have entered into a license agreement with CrystalGenomics, Inc. (KOSDAQ:083790) for China rights to CG-806 (including People’s Republic of China, Hong Kong and Macau)....

Jun 05, 2018 04:05 pm ET

Aptose Biosciences Announces Results of Annual Meeting of Shareholders

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the voting results from the Company’s...

Jun 04, 2018 07:04 am ET

Aptose Announces Two Publications of Preclinical Data Elucidating the Anticancer Mechanism of Action of APTO-253

Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced the publication of preclinical data elucidating the mechanism of action of APTO-253, the company’s clinical stage anticancer product candidate. The data are published in two separate...

May 31, 2018 07:04 am ET

APTOSE Enters into US$20 Million Common Share Purchase Agreement with Aspire Capital Fund, LLC

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that it has entered into a Common...

May 17, 2018 11:43 am ET

Aptose to Present New CG’806 Data at the 23rd Congress of the European Hematology Association

May 10, 2018 04:00 pm ET

Aptose Reports Results for the First Quarter Ended March 31, 2018

May 07, 2018 07:00 am ET

Aptose Exercises Early Option for CG-806 License From CrystalGenomics

Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) and CrystalGenomics, Inc. (KOSDAQ:083790) today announced that Aptose exercised its option under the 2016 Option Agreement to exclusively license CG-806, a first-in-class, non-covalent pan-inhibitor...

May 01, 2018 07:30 am ET

Aptose To Release First Quarter Ended March 31, 2018 Financial Results and Hold Conference Call on May 10, 2018

SAN DIEGO and TORONTO, May 01, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs...

Apr 25, 2018 07:00 am ET

Aptose Announces Appointment of Caroline M. Loewy to Board of Directors

SAN DIEGO and TORONTO, April 25, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the appointment of Caroline M. Loewy to the...

Apr 24, 2018 07:00 am ET

Aptose to Present at the Bloom Burton & Co. Healthcare Investor Conference 2018

SAN DIEGO and TORONTO, April 24, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G....

Apr 17, 2018 02:00 pm ET

Aptose Presents Preclinical Data on APTO-253 at 2018 AACR Annual Meeting

Cancer cells deficient in BRCA1 or BRCA2 function hyper-sensitive to APTO-253

Apr 16, 2018 07:30 am ET

Aptose Presents New Preclinical Data on CG’806 Pan-FLT3/ Pan-BTK Inhibitor at 2018 AACR Annual Meeting

CG’806 targets multiple pathways and kills cancer cells resistant to other FLT3 and BTK inhibitors

Apr 16, 2018 07:30 am ET

OHSU and Aptose Present New CG’806 Preclinical Data at 2018 AACR Annual Meeting

CG’806 Continues to Demonstrate Superior Activity to Other FLT3 and BTK Inhibitors Against Patient Samples

Apr 03, 2018 08:00 am ET

Aptose to Present at the H.C. Wainwright Annual Global Life Sciences Conference

SAN DIEGO and TORONTO, April 03, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G....

Mar 28, 2018 08:00 am ET

Aptose Biosciences Establishes New At-the-Market Facility

SAN DIEGO and TORONTO, March 28, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that it has...

Mar 27, 2018 04:15 pm ET

Aptose Reports Results for the Fourth Quarter and Year Ended December 31, 2017

Conference Call and Webcast at 5pm EDT Today

Mar 15, 2018 07:05 am ET

Aptose to Present New CG’806 and APTO-253 Data at the 2018 AACR Annual Meeting

SAN DIEGO and TORONTO, March 15, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that preclinical data for...

Mar 08, 2018 07:00 am ET

Aptose To Release Fourth Quarter and Year End December 31, 2017 Financial Results and Hold Conference Call on March 27, 2018

SAN DIEGO and TORONTO, March 08, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs...

Mar 07, 2018 07:00 am ET

Aptose Biosciences Announces Exclusive License Agreement for Dual BET/Kinase Targeting Program With OHM Oncology

SAN DIEGO, March 07, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced an exclusive global license agreement that provides OHM...

Mar 06, 2018 07:00 am ET

Aptose to Participate in Upcoming Investor Conferences In March 2018

SAN DIEGO and TORONTO, March 06, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G....

Feb 07, 2018 04:01 pm ET

Aptose Biosciences Files New Preliminary Base Shelf Prospectus to Replace Expired Base Prospectus

SAN DIEGO and TORONTO, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that it has...

Jan 02, 2018 07:30 am ET

Aptose Biosciences to Present at Biotech Showcase™ 2018 Conference

SAN DIEGO and TORONTO, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President...

Dec 26, 2017 07:30 am ET

FDA Grants Orphan Drug Designation to Aptose Biosciences for CG’806 in Acute Myeloid Leukemia

SAN DIEGO and TORONTO, Dec. 26, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CG’806, a highly potent pan-FLT3/pan-BTK inhibitor, for the...

Dec 11, 2017 04:04 pm ET

Aptose Presents New Preclinical Data on CG’806 pan-FLT3/pan-BTK Inhibitor at ASH 59th Annual Meeting

Data elucidate unique ability of CG’806 to kill a broad range of AML cells by suppressing multiple pathways, to overcome resistance caused by bone marrow stromal cells, and to act synergistically with other agents

Dec 11, 2017 04:04 pm ET

OHSU and Aptose Present CG’806 Preclinical Data at ASH 59th Annual Meeting

CG’806 reveals broad and potent single agent activity, and enhanced activity when combined with Bcl-2 or BET inhibitors, against AML and CLL patient samples

Nov 14, 2017 04:00 pm ET

Aptose Reports Results for the Third Quarter Ended September 30, 2017

Conference Call and Webcast at 5pm EST Today

Nov 07, 2017 08:00 am ET

Aptose To Release Third Quarter Ended September 30, 2017 Financial Results and Hold Conference Call on November 14, 2017

SAN DIEGO and TORONTO, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Aptose) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, will release its financial results for the quarter ended...

Nov 01, 2017 11:14 am ET

Aptose to Present New CG’806 Data at the 2017 ASH Annual Meeting

SAN DIEGO and TORONTO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO), (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that preclinical data for...

Aug 08, 2017 04:05 pm ET

Aptose Reports Results for the Second Quarter Ended June 30, 2017

SAN DIEGO and TORONTO, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced financial results for the three months ended June 30, 2017 and reported on corporate developments. Unless specified otherwise, all amounts are in Canadian dollars....

Aug 03, 2017 08:30 am ET

Aptose Biosciences to Present at Canaccord Genuity 37th Annual Growth Conference

SAN DIEGO and TORONTO, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the Canaccord Genuity 37th Annual Growth Conference on Thursday, August 10th, 2017 at 11:30 a.m. ET at the Intercontinental Hotel, Boston, MA....

Aug 01, 2017 08:30 am ET

Aptose To Release Second Quarter Ended June 30, 2017 Financial Results and Hold Conference Call on August 8, 2017

SAN DIEGO and TORONTO, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Aptose) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended June 30, 2017, on Tuesday, August 8, 2017 after the close of the market. The company intends to host a conference call the same day at 5:00 p.m. ET to discuss the financial results. ...

Jun 06, 2017 04:05 pm ET

Aptose Biosciences Announces Results of Annual Meeting of Shareholders

SAN DIEGO and TORONTO, June 06, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced the voting results from the Company’s annual meeting of shareholders held today, June 6, 2017 (the “Meeting”)....

May 11, 2017 04:02 pm ET

Aptose Reports Results for the First Quarter Ended March 31, 2017

SAN DIEGO and TORONTO, May 11, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced financial results for the three months ended March 31, 2017 and reported on corporate developments. Unless specified otherwise, all amounts are in Canadian dollars....

Apr 24, 2017 08:30 am ET

Aptose To Release First Quarter Ended March 31, 2017 Financial Results and Hold Conference Call on May 11, 2017

SAN DIEGO and TORONTO, April 24, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Aptose) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended March 31, 2017, on Thursday May 11, 2017 after the close of the market. The company intends to host a conference call the same day at 5:00 p.m. ET to discuss the financial results. ...

Mar 27, 2017 08:00 am ET

Aptose Announces Planned Departure of Chief Business Officer

SAN DIEGO and TORONTO, March 27, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) (“Aptose” or the “Company”), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that Mr. Avanish Vellanki, Senior Vice President and Chief Business Officer, tendered his resignation with the Company. The resignation is effective immediately, and the Board of Directors does not contemplate replacing Mr. Vellanki at this time. Aptose is focused on the development of CG’806, an oral preclinical compound bei...

Feb 02, 2017 07:00 am ET

Aptose Biosciences to Present at Canaccord Genuity Rare Disease Biopharma 1x1 Day

SAN DIEGO and TORONTO, Feb. 02, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer and Gregory Chow, Senior Vice President and Chief Financial Officer, will participate in the upcoming Canaccord Genuity Rare Disease Biopharma 1x1 Day to be held on February 6, 2017 at the InterContinental Barclay Hotel, New York, NY. ...

Jan 05, 2017 08:00 am ET

Aptose Biosciences to Present at Biotech Showcase 2017 Conference

SAN DIEGO and TORONTO, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the upcoming Biotech ShowcaseTM 2017 Conference on Tuesday, January 10th at 9:00 a.m. PST in San Francisco, CA....

Dec 29, 2016 08:15 am ET

IIROC Trade Resumption - APS

TORONTO, Dec. 29, 2016 /CNW/ - Trading resumes in:

Dec 29, 2016 08:13 am ET

IIROC Trading Halt - APS

TORONTO, Dec. 29, 2016 /CNW/ - The following issues have been halted by IIROC:

Nov 14, 2016 07:21 pm ET

Aptose Biosciences Reports Financial Results for the Third Quarter Ended September 30, 2016

SAN DIEGO and TORONTO, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced unaudited financial results for the three months ended September 30, 2016 and reported on corporate developments. Unless specified otherwise, all amounts are in Canadian dollars....

Nov 10, 2016 07:00 am ET

Aptose To Release Third Quarter Ended September 30, 2016 Financial Results and Hold Conference Call on November 15, 2016

SAN DIEGO and TORONTO, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Aptose) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended September 30, 2016, on Monday, November 14, 2016 after the close of the market. The company intends to host a conference call the following morning on Tuesday, November 15, 2016 at 8:30 a.m. ET to discuss the financial results. ...

Nov 03, 2016 04:15 pm ET

Aptose to Present New APTO-253 Data at the 2016 ASH Annual Meeting

SAN DIEGO and TORONTO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that new preclinical data for its lead investigational anticancer therapeutic APTO-253 will be presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 3-6, 2016, in San Diego, CA....

Oct 13, 2016 07:00 am ET

Aptose Provides Update on FDA Clinical Hold of APTO-253

SAN DIEGO and TORONTO, Oct. 13, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that it received a response from the U.S. Food and Drug Administration (FDA) regarding the clinical hold of Aptose’s Phase 1b clinical trial of APTO-253 in patients with hematologic cancers requesting additional information and informing Aptose that the hold would not be removed until this information is submitted and reviewed. The FDA resp...

Sep 12, 2016 08:00 am ET

Aptose Submits Formal Response to Clinical Hold for APTO-253

SAN DIEGO and TORONTO, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, announced today that it has submitted a formal response to the U.S. Food and Drug Administration (FDA) regarding the previously announced clinical hold of Aptose’s Phase 1b clinical trial of APTO-253 in patients with hematologic cancers. Aptose provided responses to all of the questions cited in the clinical hold letter issued by the FDA....

Aug 09, 2016 04:15 pm ET

Aptose Biosciences Reports Financial Results for the Second Quarter Ended June 30, 2016

SAN DIEGO and TORONTO, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced unaudited financial results for the three months ended June 30, 2016 and reported on corporate developments. Unless specified otherwise, all amounts are in Canadian dollars....

Aug 09, 2016 08:00 am ET

Aptose Biosciences to Present at Canaccord Genuity 36th Annual Growth Conference

SAN DIEGO and TORONTO, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the upcoming Canaccord Genuity 35th Annual Growth Conference on Thursday, August 11th at 2:00 p.m. ET at the InterContinental Hotel Boston, MA. Dr. Rice will provide a corporate overview of the Company’s recent activities and strategic direction....

Aug 04, 2016 04:15 pm ET

Aptose To Release Second Quarter Ended June 30, 2016 Financial Results and Hold Conference Call on August 9, 2016

SAN DIEGO and TORONTO, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Aptose) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended June 30, 2016, on Tuesday, August 9, 2016 after the close of the market. The company intends to host a conference call on the same day at 5:00 p.m. ET to discuss the financial results. ...

Jun 21, 2016 04:10 pm ET

Aptose Biosciences Announces Results of Annual Meeting of Shareholders

SAN DIEGO and TORONTO, June 21, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) (“Aptose” or the “Company”) today announced the voting results from the Company’s annual meeting of shareholders held on June 21st in Toronto, Ontario, Canada (the “Meeting”)....

Jun 21, 2016 08:00 am ET

Aptose Biosciences Provides Corporate Update in Advance of Annual Meeting of Shareholders

SAN DIEGO and TORONTO, June 21, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) (“Aptose” or the “Company”) today provided a corporate update in advance of the Company’s Annual General Meeting of shareholders to be held today at 10:00 AM ET in Toronto, Ontario, Canada....

Jun 08, 2016 08:00 am ET

Aptose Biosciences and CrystalGenomics Announce Exclusive Agreement for Non-Covalent BTK / FLT3 / AURK Inhibitor

TORONTO and SEOUL, South Korea, June 08, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) and CrystalGenomics, Inc. (KOSDAQ:083790) today announced an exclusive global option and license agreement focused on the development of CG026806 (CG’806), a first-in-class, highly potent, non-covalent small molecule inhibitor of the Bruton’s tyrosine kinase (BTK), FMS-like tyrosine kinase 3 (FLT3) and the Aurora kinases (AURK). Further to enacting the agreement, Aptose expects to undertake Investigational New Drug (IND) enabling studies immediately, and, if it exercises its op...

Ad blocking detected

You've reached your 10 company page visit this month!

Aptose Biosciences Inc. (T:APS)

Business Focus: Biotechnology & Medical Research (NEC)